MedTrace Logo

The Effect of Valproate on Benzodiazepine Withdrawal Severity

NCT00570219 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-10-17

No results posted yet for this study

Summary

The aim of this study is to determine whether valproate is effective in the treatment of benzodiazepine withdrawal symptoms in subjects receiving maintenance treatment for opiate dependence.

Conditions

  • Substance Withdrawal Syndrome

Interventions

DRUG

valproate

Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.

Sponsors & Collaborators

  • University of Helsinki

    lead OTHER

Principal Investigators

  • Helena Vorma, MD, Ph.D · Deputy chief physician, Helsinki University Central Hospital, Department of Psychiatry

  • Katila Heikki, Md, Ph.D · Chief medical officer, Helsinki University Central Hospital, Department of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00570219 on ClinicalTrials.gov